articleThe Lancet OncologyApr 17, 2023Closed access

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

Chinese PLA General Hospital · Tokyo National Hospital · +26 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

283
total citations
FWCI
83.05
Percentile
100%
References
32
Citations per year

Authors

24

Topics & keywords

Keywords
  • Medicine
  • Chemotherapy
  • Internal medicine
  • Placebo
  • Performance status
  • Capecitabine
  • Oncology
  • Gastroenterology
UN Sustainable Development Goals
  • No poverty
No related works found for this paper.